PHVS Overview
Upcoming Projects (PHVS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PHVS)
-
Exploring the Future of Hereditary Angioedema Treatment: A Deep Dive into Pharvaris's Deucrictibant and Astria Therapeutics' STAR-0215 Developments
Tickers: PHVS, ATXS
Executed On: Feb 07, 2024 at 04:30 PM EST -
Discussing HAE and sebetralstat as an on-demand therapy in the KONFIDENT trial from Kalvista Pharmaceuticals
Tickers: KALV, PHVS
Executed On: Jul 06, 2023 at 03:00 PM EDT -
An overview of the hereditary angioedema (HAE) treatment landscape with a focus on new therapies in development by Kalvista, Astria, and Pharvaris
Tickers: PHVS, KALV, ATXS
Executed On: Apr 05, 2023 at 04:00 PM EDT -
A Second Take: Discussing Pharvaris' PHVS416 in treating Hereditary angioedema attacks
Ticker: PHVS
Executed On: Feb 03, 2023 at 04:00 PM EST -
Discussing Pharvaris' PHVS416 in treating Hereditary angioedema attacks
Ticker: PHVS
Executed On: Jan 18, 2023 at 01:00 PM EST
Expired Projects (PHVS)
-
Exploring the Frontiers of HAE Management: A Comprehensive Evaluation of Deucrictibant in Prophylactic Treatment
Ticker: PHVS
Execute By: Apr 30, 2024 -
A Deep Dive into Pharvaris' Deucrictibant for Prophylactic Treatment with a Focus on the P2 CHAPTER-1 trial
Ticker: PHVS
Execute By: Feb 29, 2024
Upcoming & Overdue Catalysts (PHVS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (PHVS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!